Report: Injectable antibodies top growth chart

10/11/2007 | NYTimes.com

Sales of injectable monoclonal antibodies will grow 14% annually from 2006 to 2012, preserving their status as the fastest-growing class of drugs during the next five years, market analyst Datamonitor says in its latest report. Antibody-based drugs already are popular for the treatment of cancer and rheumatoid arthritis and currently generate $20 billion in global revenue.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD